altinicline-maleate and Dizziness

altinicline-maleate has been researched along with Dizziness* in 1 studies

Trials

1 trial(s) available for altinicline-maleate and Dizziness

Article	Year
Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology, 2006, Feb-14, Volume: 66, Issue:3 This randomized, placebo-controlled, 5-week Phase II trial evaluated the safety and tolerability of SIB-1508Y, a selective alpha4beta2 nicotinic acetylcholine receptor agonist, in 77 individuals with early Parkinson disease. Lightheadedness was a common dosage-related adverse effect at higher dosages, leading to frequent dosage reduction, drug discontinuation, and eventual trial redesign. A maximally tolerated dosage of 10 mg daily was identified. No antiparkinsonian or cognitive-enhancing effects were demonstrated in this trial. Topics: Aged; Antiparkinson Agents; Dizziness; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Parkinson Disease; Pyridines; Pyrrolidines; Treatment Outcome	2006

Article

Year

Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease.

Neurology, 2006, Feb-14, Volume: 66, Issue:3

This randomized, placebo-controlled, 5-week Phase II trial evaluated the safety and tolerability of SIB-1508Y, a selective alpha4beta2 nicotinic acetylcholine receptor agonist, in 77 individuals with early Parkinson disease. Lightheadedness was a common dosage-related adverse effect at higher dosages, leading to frequent dosage reduction, drug discontinuation, and eventual trial redesign. A maximally tolerated dosage of 10 mg daily was identified. No antiparkinsonian or cognitive-enhancing effects were demonstrated in this trial.

Topics: Aged; Antiparkinson Agents; Dizziness; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Parkinson Disease; Pyridines; Pyrrolidines; Treatment Outcome

2006